Neuropsychiatry Franchise

Sage is working to understand the underlying reasons for disorders of the brain and central nervous system (CNS). We hope this science will help us develop potential therapies that may address treatment gaps for patients with brain health disorders.

Our lead neuropsychiatry investigational compound, dalzanemdor (SAGE-718), has a unique way of modulating certain receptors in the brain. These receptors are thought to play a key role in how our brain processes information.

Sage is exploring dalzanemdor (SAGE-718) in Huntington’s Disease. Ongoing studies aim to evaluate whether dalzanemdor (SAGE-718) may have the potential to improve cognitive and/or behavioral symptoms for Huntington’s Disease.

We are using our unique development approach to systemically evaluate our drug candidates in Huntington’s Disease.

LEARN MORE ABOUT OUR APPROACH TO BRAIN HEALTH DISORDERS

Huntington's Disease

Huntington’s Disease is a rare, inherited neurodegenerative disease that progresses over time. Up to 30,000 adults are diagnosed with Huntington’s Disease in the U.S. each year. Symptoms usually appear between ages 30–45, worsen over the following 15–20 years, and ultimately lead to death. Psychiatric and cognitive symptoms can severely affect people with Huntington’s Disease, particularly in the earlier stages of the disease.